CN104822702B - α-MSH和γ-MSH类似物 - Google Patents

α-MSH和γ-MSH类似物 Download PDF

Info

Publication number
CN104822702B
CN104822702B CN201380062117.6A CN201380062117A CN104822702B CN 104822702 B CN104822702 B CN 104822702B CN 201380062117 A CN201380062117 A CN 201380062117A CN 104822702 B CN104822702 B CN 104822702B
Authority
CN
China
Prior art keywords
lys
gly
arg
phe
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380062117.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104822702A (zh
Inventor
托马斯·伯森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Txp Pharmacy Stock Co Ltd
Original Assignee
Txp Pharmacy Stock Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Txp Pharmacy Stock Co Ltd filed Critical Txp Pharmacy Stock Co Ltd
Publication of CN104822702A publication Critical patent/CN104822702A/zh
Application granted granted Critical
Publication of CN104822702B publication Critical patent/CN104822702B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380062117.6A 2012-10-19 2013-10-21 α-MSH和γ-MSH类似物 Active CN104822702B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261716032P 2012-10-19 2012-10-19
US61/716,032 2012-10-19
PCT/EP2013/071935 WO2014060606A1 (en) 2012-10-19 2013-10-21 Alpha- and gamma-msh analogues

Publications (2)

Publication Number Publication Date
CN104822702A CN104822702A (zh) 2015-08-05
CN104822702B true CN104822702B (zh) 2019-07-30

Family

ID=49448156

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380062117.6A Active CN104822702B (zh) 2012-10-19 2013-10-21 α-MSH和γ-MSH类似物

Country Status (12)

Country Link
US (3) US9217023B2 (enExample)
EP (2) EP2944650A1 (enExample)
JP (1) JP6429782B2 (enExample)
CN (1) CN104822702B (enExample)
AU (1) AU2013333765B2 (enExample)
CA (1) CA2888277C (enExample)
DK (1) DK2722340T3 (enExample)
ES (1) ES2538702T3 (enExample)
HU (1) HUE025870T2 (enExample)
PL (1) PL2722340T3 (enExample)
RU (1) RU2668791C2 (enExample)
WO (1) WO2014060606A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013333765B2 (en) 2012-10-19 2017-12-07 Txp Pharma Gmbh Alpha- and gamma-MSH analogues
HUE052977T2 (hu) * 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
WO2015162483A1 (en) * 2014-04-22 2015-10-29 Txp Pharma Gmbh Alpha- and gamma-msh analogues
WO2016066702A1 (en) * 2014-10-28 2016-05-06 Clinuvel Ag Inflammatory disease
US20170304406A1 (en) * 2014-10-28 2017-10-26 Clinuvel Ag New indication for alpha-msh analogues
WO2017068020A1 (en) 2015-10-20 2017-04-27 Txp Pharma Gmbh W-peptide analog
LT3773558T (lt) 2019-05-10 2022-09-12 Synact Pharma Aps Kompleksinis artrito gydymas
CA3190959A1 (en) 2020-08-12 2022-02-17 Txp Pharma Ag Exendin-4 peptide analogues
JP2024522348A (ja) * 2021-05-27 2024-06-18 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｃ３ｒアゴニストペプチド
WO2022268825A1 (en) 2021-06-21 2022-12-29 Synact Pharma Aps Phenyl pyrrole aminoguanidine salts and formulations
WO2024030977A2 (en) * 2022-08-03 2024-02-08 Sightstream Biotherapeutics, Inc. Novel melanocortin analogs
CN117106057B (zh) * 2022-08-19 2024-11-01 南京汉欣医药科技有限公司 一种高纯的人促肾上腺皮质激素或其类似物及其规模化制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046283A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
CN101273059A (zh) * 2005-08-26 2008-09-24 阿克申制药公司 治疗活性的α-MSH类似物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5597894A (en) 1995-06-05 1997-01-28 The Louisiana State University Medical Center Foundation Multi-tyrosinated somatostatin analogs
CN1246868A (zh) 1996-12-17 2000-03-08 扇形支撑剑桥有限公司 黑皮素
SE9801571D0 (sv) 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
AU7593001A (en) 2000-07-14 2002-01-30 Zycos Inc Alpha-msh related compounds and methods of use
US8912144B2 (en) 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
EP2236151B1 (en) * 2005-07-08 2012-05-23 Ipsen Pharma Melanocortin receptor ligands
AU2013333765B2 (en) 2012-10-19 2017-12-07 Txp Pharma Gmbh Alpha- and gamma-MSH analogues
HUE052977T2 (hu) 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
WO2015162483A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Alpha- and gamma-msh analogues
WO2015162486A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046283A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
CN101273059A (zh) * 2005-08-26 2008-09-24 阿克申制药公司 治疗活性的α-MSH类似物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
David R. Bard.Potential imaging agents for melanoma based on an active analogue of α-melanocyte-stimulating hormone.《Drug Delivery》.2008,第2卷(第1期), *
Potential imaging agents for melanoma based on an active analogue of α-melanocyte-stimulating hormone;David R. Bard;《Drug Delivery》;20080927;第2卷(第1期);第73页第一段第8-19、29-31行，第74页图1中d *

Also Published As

Publication number Publication date
US9486495B2 (en) 2016-11-08
EP2722340A1 (en) 2014-04-23
US9217023B2 (en) 2015-12-22
PL2722340T3 (pl) 2015-08-31
EP2944650A1 (en) 2015-11-18
EP2722340B1 (en) 2015-03-04
BR112015008767A2 (pt) 2017-07-04
RU2015118576A (ru) 2016-12-10
HUE025870T2 (en) 2016-05-30
US9951116B2 (en) 2018-04-24
US20170174738A1 (en) 2017-06-22
CA2888277C (en) 2023-09-05
RU2668791C2 (ru) 2018-10-02
DK2722340T3 (en) 2015-06-08
CA2888277A1 (en) 2014-04-24
AU2013333765B2 (en) 2017-12-07
US20160074469A1 (en) 2016-03-17
WO2014060606A1 (en) 2014-04-24
CN104822702A (zh) 2015-08-05
US20140155328A1 (en) 2014-06-05
JP6429782B2 (ja) 2018-11-28
ES2538702T3 (es) 2015-06-23
AU2013333765A1 (en) 2015-05-28
HK1197552A1 (en) 2015-01-23
JP2015534972A (ja) 2015-12-07

Similar Documents

Publication Publication Date Title
CN104822702B (zh) α-MSH和γ-MSH类似物
ES2854353T3 (es) Análogos péptidicos con sonda(s) aminoacídicas ramificadas
CA2530024A1 (en) Melanocortin receptor 4(mc4) agonists and their uses
US20150297672A1 (en) Alpha- and gamma-MSH analogues
US20150376254A1 (en) Gamma-msh analogues
WO2017068020A1 (en) W-peptide analog
WO2023161323A1 (en) Annexin a1-derived polypeptide analogues
US20250388632A1 (en) Annexin a1-derived polypeptide analogues
HK1197552B (en) Alpha- and gamma-msh analogues
US20230303640A1 (en) Exendin-4 peptide analogs
BR112015008767B1 (pt) Peptídeo, composição farmacêutica e uso do peptídeo
HK1234347A1 (en) Peptide analogues with branched amino acid probe(s)
HK1234347B (en) Peptide analogues with branched amino acid probe(s)

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant